IBM and Celgene will be joining forces to protect patients as the two companies will be mixing their technologies so as to help doctors and create a drug safety program.
IBM, the computing giant company, has been developing and implementing their own Artificial Intelligence (AI) program, called Watson, which has until now been mostly used in the business and technology domains.
Now, thanks to the collaboration with Celgene, the IBM Watson will be opening up a new division called IBM Watson for Patient Safety.
Celgene, the biopharmaceutical global company has in its turn been testing and releasing new products that mean to fight disease and improve patient safety.
The collaboration between IBM and Celgene will seek to offer a better, more accurate database for drug prescriptions and treatments.
The process should work and combine the two companies’ principal assets in the area, the IBM Watson’s processing speed, and the Celgene database.
IBM Watson would be used as data processing tool as the AI-powered system will process and synthesize the most important data points gathered from a variety of sources.
Electronic medical records which have been turned anonymous, medical claims and similar other such databases would be processed and would ultimately contribute towards a better decision-making process in the development of the various medical products.
The IBM and Celgene future platform would permit such a development process as the mix would account for both a rapid data collection system and an automated analysis process which would denote the best results.
According to John Freeman, the global safety and risk management Celgene vice president, current drug utilization and prescription techniques are based on relatively small databases.
The mixing of IBM’s Watson technology with the medical data would allow for a better understanding of large scale databases. This would, in turn, lead to a better communication between pharma companies and the drug regulators.
The pharma company and drug maker could also use the database processing system so as to look for and have access to a larger area of possible side effects and adverse reactions.
This would, in turn, lead to more efficient products and an increase in patient safety standards and measures. It could also account for a more cost-efficient treatment as a better understanding of the potential medicine would allow for a faster, safer trial period, marked by fewer failures and more efficiency.
As the IBM Watson technology is AI based, it would also account for the system’s ability to learn, process, and synthesize new data, to essentially grow. Such a continuous update in the databases could result in more effective treatments as it would also lower the potentially adverse reactions.
The IBM and Celgene collaboration hopes to bring a new, cost-effective, patient protection as its large database processes should allow for better treatment therapies.
Image Source: Wikimedia